Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients.
Alessandra Fabi(Agostino Gemelli University Polyclinic), F. Cognetti(Sapienza University of Rome), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Giuliana D’Auria(Ospedale di Belcolle), Giulio Metro(University of Perugia), Michelangelo Russillo(National Cancer Institute), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Federica Cuppone(Italian Medicines Agency), Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori)
Cited by 0
Related Papers
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240